A PYMNTS Company

UK/ US Shire, Baxalta to announce $30bn merger as soon as Monday

By  |  January 7, 2016
Rare disease drugmaker Shire Pharmaceuticals is preparing to announce its roughly $32.5 billion acquisition of US peer Baxalta International as early as Monday, according to people familiar with the matter.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The deal would come after Reuters first reported on Dec. 22 that Shire’s latest offer for Baxalta had met the latter’s valuation expectations. It would be one of the healthcare sector’s largest mergers in 2016.

    The acquisition would mark the culmination of a long pursuit hinged partly on how much cash Shire could offer without triggering additional taxes for Baxalta. Reuters first reported Shire’s renewed effort to court Baxalta in November.

    The deal would mark a strong start to healthcare M&A in 2016, after the sector saw it’s biggest deal making streak in history last year.

    Full content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.